Case Study

Successful Full-Service, Randomized Pancreatic Cancer Phase II Trial

GettyImages-1402639208 Pancreatic Cancer

A clinical-stage biopharmaceutical company was looking to collaborate on a randomized Phase II study conducted at multiple centers. The study aimed to evaluate the efficacy of a modified synthetic peptide in patients diagnosed with exocrine pancreatic cancer. To accomplish these goals, the sponsor needed help with biostatistics and programming, data management, monitoring and site management, medical safety, quality assurance, and medical writing.

Learn how they were able to reach a unanimous decision after a safety review committee data review meeting to close Phase II and advance to Phase III.

access the Case Study!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader